Department of Medicine, Editorial Office, Italy
Review
In Renal Cell Carcinoma, the Role of Natural Supplement Compounds as Anticancer Agents
Author(s): Fabio Ferri
Renal Cell Carcinoma (RCC) is the most common kidney cancer that arises from the renal tubules, accounting for around 85% of all malignant kidney cancers. Every year, about 60,000 new instances of RCC are reported, with approximately 14,000 people dying from the disease. In the United States and other countries, the frequency of this has been steadily growing. A better understanding of RCC's molecular biology and genetics has revealed multiple signalling pathways implicated in the cancer's growth. Agents licenced by the Food and Drug Administration (FDA) that target these pathways have been reported to make significant advancements in the treatment of RCC. Because of their therapeutic value and enhanced survival in patients with metastatic disease, these medications have become the treatments of choice. Patients, on the other hand, eventually relapse and acquire resistance to .. View More»
DOI:
10.35248/1840-4529.22.14.341
